Recent advances in 99mTc radiopharmaceuticals

Annals of Nuclear Medicine

Volumn 16, Issue 2, 2002, Pages 79-93

  Arano, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Bifunctional chelating agent; Conjugated design; Integrated design; Peptides; Proteins; Radiopharmaceutical; Technetium 99m

Indexed keywords

AMINE; CARRIER PROTEIN; CHELATING AGENT; DITHIOCARBAMIC ACID DERIVATIVE; DITHIOL DERIVATIVE; LIGAND; ORGANOMETALLIC COMPOUND; OXIME; PEPTIDE; PROTEIN; RADIOPHARMACEUTICAL AGENT; RECEPTOR; RHENIUM COMPLEX; SEMICARBAZONE DERIVATIVE; TECHNETIUM 99M; TECHNETIUM COMPLEX; DIAGNOSTIC AGENT; TECHNETIUM;

BONE; BRAIN BLOOD FLOW; DIAGNOSTIC IMAGING; DRUG DESIGN; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; HEART MUSCLE BLOOD FLOW; HISTORY OF MEDICINE; HUMAN; IMAGING SYSTEM; KIDNEY; LIVER; NUCLEAR MEDICINE; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS; ANIMAL; BLOOD FLOW; BRAIN CIRCULATION; CHEMICAL STRUCTURE; CHEMISTRY; CORONARY ARTERY BLOOD FLOW; HEART; SCINTISCANNING;

ANIMALS; CEREBROVASCULAR CIRCULATION; CHELATING AGENTS; CORONARY CIRCULATION; DRUG DESIGN; HEART; HUMANS; MOLECULAR STRUCTURE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; TECHNETIUM;

EID: 0035999836     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02993710     Document Type: Review

References (142)

1. 99mTc-bifunctional radiopharmaceutical containing dithiosemicarbazone chelate group
2. Tc-99m bifunctional radiopharmaceutical from a glucose derivatives: A potential agent for brain study
3. Development of Tc-99m-phenylalkylamine bifunctional radiopharmaceuticals for myocardial imaging
4. 2 core
5. Synthesis and Characterization of hexakis(alkylisocyanide) and hexakis(arylisocyanide) complexes of Technetium(I)
6. Synthesis and structure of bis(diethyldithiocarbamato)nitrido-technetium (V): A technetium-nitrogen triple bond
7. Preparation and X-ray structure of trans-dioxo(1,4,8,11-tetraazacyclotetradecane) technetium (V) perchlorate hydrate
8. Synthesis and biodistribution of neutral lipid-soluble Tc-99m complexes that cross the blood-brain barrier
9. Stable and lipophilic technetium-99m dithiosemicarbazone complexes with 5-6-5 membered chelate ring structure
10. Characterization of technetium-99m complexes of pentane-2,4-dione bis(N-methylthiosemicarbazone)
11. 99mTc-PnAO); a potential brain radiopharmaceutical
12. Development of I-123 labeled amines for brain studies: Localization of 1-123 lodophenylalkylamines in rat brain
13. A new brain perfusion imaging agent: [I-123]HIPDM: N,N,N″-trimethyl-N′-(2-hydroxy-3-amethyl-5-iodobenzyl) -1,3-propanediamine
14. Brain imaging agents: Synthesis and characterization of (N-pipeperidylethyl)hexamethyl diaminodithiolate oxo technetium (V) complexes
15. Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 1: Pharmacology of technetium-99m ECD in nonhuman primates
16. The interaction of 2-methyl-2-amino-3-butanone oxime with some transition metal
17. 2]
18. Technetium-99m d.1-HMPAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood flow
19. The retention mechanism of technetium-99m-HM-PAO: Intracellular reaction with glutathione
20. Synthesis and biological studies of neutral technetium-(V) complexes containing NNOS donor sets
21. Technetium-99m-MRP20, a potential brain perfusion agent: In vivo biodistribution and SPECT studies in non-primate animals
22. Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents
23. 99mTc aminobisthiolato/monothiolato "3 + 1" mixed ligand complexes: Structure-activity relationships and preliminary in vivo validation as brain blood flow imaging agents
24. 99mTcO(SNS)(S)] mixed ligand complexes with glutathione: Isolation and characterization of the product
25. Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: A proposed mechanism of brain retention
26. Cationic Tc-99m complexes as potential myocardial imaging agents
27. Effect of coronary blood flow on uptake and washout of Tc-99m DMPE and TI-201
28. 6
29. Synthesis, characterization, and electrochemical properties of technetium complexes containing both tetradentate schiff base and monodentate tertiary phosphine ligands: Single-crystal structure of trans- (N,N′-ethylene-bis(acetylacetone iminato)bis(triphenyl-phosphine) technetium (III) hexafluorophosphate
30. 3 and thallium-201 for detection of coronary artery disease in humans
31. 99Tc NMR
32. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging
33. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent
34. Chemical and in vivo studies of the anion oxo[N,N′-ethylenebis(2-mercaptoacetimido)technetate (V)
35. A new Tc-99-labeled myocardial imaging agent, hexakis(t-butylisonitrile)-technetium(I) [Tc-99m TBI]: Initial experience in the human
36. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells
37. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence
38. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts
39. Bis(dithiocarbamato) nitrido technetium-99m radiopharmaceuticals: A class of neutral myo-cardial imaging agents
40. Myocardial kinetics of TcN-NOET: A neutral lipophilic complex tracer of regional myocardial blood flow
41. Myocardial perfusion imaging with technetium-99m-Tc NOET: Comparison with thallium-201 and coronary angiography
42. Subcellular distribution of technetium-99m-N-NOEt in rat myocardium
43. Search for Tc-99m labeled DTS bifunctional radiopharmaceutical: Role of functional groups in myocardial accumulation
44. Design of bifunctional radiopharmaceutical for the development of Tc-99m complex for myocardial imaging agents
45. In the procurement of a neutral and compact monomeric complex of dithiosemicarbazone (DTS) derivative: Tc-99m-KTS
46. Technepine: A high-affinity 99m-technetium probe to label the dopamine transporter in brain by SPECT imaging
47. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1
48. 99mTc-TRODAT-1 imaging
49. Technetium-labeled and rhenium-labeled progestins - Synthesis, receptor binding and in vivo distribution of an 11 beta-substituted progestin labeled with technetium-99 and rhenium-186
50. Progestin-rhenium complexes: Metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy
51. 2-metal conjugate
52. Technetium-99m-labeled medium-chain fatty acid analogues metabolized by beta-oxidation: Radiopharmaceutical for assessing liver function
53. Novel technetium ligands with affinity for the muscarinic cholinergic receptor
54. Selective formation of heterodimeric bis-bidentate aminothiol-oxometal complexes of rhenium(V)
55. Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V) - Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones
56. Technetium(V) and rhenium(V) complexes for 5-HT2A serotonin receptor binding: Structure-affinity considerations
57. Tc-99m-labeled tropanes as dopamine transporter imaging agents
58. Integrated "3 + 1" oxorhenium(V) complexes as estrogen mimics
59. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous; connective and soft tissues
60. 99mTc-pertechnetate in selected soft and hard tissues
61. 99mTc for skeletal imaging
62. 99mTc skeletal imaging agents
63. 2O. Implication for the chemistry of technetium-99m-diphosphonate skeletal imaging agents
64. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate
65. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases
66. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases
67. Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer
68. Hydrogen-I and gallium-71 nuclear magnetic resonance study of gallium citrate in aqueous solution
69. 99mTc- dimercaptosuccinate complex as a tumor imaging agent
70. Tc(V)-DMS tumor imaging agent: Tc-complex dissociation equilibra, a relevant factor in tumor localization
71. Search for polynuclear pentavalent technetium complex of dimercaptosuccinic acid [Tc(V)-DMS] tumour localization mechanism. I. Medullary thyroid carcinoma animal model
72. pH sensitive properties of Tc(V)-DMS: Analytical and in vitro cellular studies
73. Tc(V)-DMS tumor localization mechanism: A pH-sensitive Tc(V)-DMS-enhanced target/nontarget ratio by glucose-mediated acidosis
74. Tc-99m (V) dimercaptosuccinic acid scintigraphy for bone and soft tissue lesions
75. m-dimercaptosuccinic acid: A comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions
76. 99mTc DMSA(V) scintigraphy
77. The role of Tc-99m (V) DMSA scintigraphy in the evaluation of superscan on bone scintigraphy
78. Pentavalent Tc-99m dimercaptosuccinic acid imaging of hepatocellular carcinoma
79. Imaging of soft tissue tumors with Tc(V)-99m dimercaptosuccinic acid. A new tumor-seeking agent
80. 186Re(V)-DMS
81. Conformational stability, folding and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli
82. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
83. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
84. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: Comparison to radioiodinated fragments
85. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
86. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms
87. 1〉-octreotide, a potential radiopharmaceutical for imaging of somato-statin receptor-positive tumors - Synthesis, radiolabeling and in vitro validation
88. 1〉-octreotide for detection of somato-statin receptor-positive tumors in rats
89. Reduction-mediated technetium-99m labeling of monoclonal antibodies
90. 99mTc-labeled monoclonal antibody
91. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m
92. Radioactive labeling of antibody: A simple and efficient method
93. Reassessment of diethylenetri-aminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative
94. Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability
95. 99mTc Labeling of Proteins: Initial evaluation of a novel diaminedithiol bifunctional chelating agent
96. Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: Conjugation chemistry, immunoreactivity and kit formulation
97. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent
98. Labeling cyclic glycoprotein IIb/IIla receptor antagonists with Tc-99m by the preformed chelate approach: Effects of chelators on properties of [Tc-99m]chelator-peptide conjugates
99. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m
100. 99mTc-radiolabeled antibody Fab'-chelator conjugate
101. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats
102. 99mTc radiopharmaceuticals
103. 99mTc labeling of polypeptides
104. Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: Comparison with indium-111-DTPA-IgG
105. Tumor imaging with technetium-99m-labeled hydrazinonicotinamide- Fab'conjugates
106. Technetium-99m-labeled chemotactic peptides in acute infection and sterile inflammation
107. Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: Evidence for a receptor-specific mechanism
108. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection
109. Somatostatin receptor-binding peptides labeled with technetium-99m: Chemistry and initial biological studies
110. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides
111. 3]octreotide
112. 99m-Technetium-labelled peptide-HYNIC conjugates: Effects of lipophilicity and stability on biodistribution
113. Technetium-99m somatostatin analogues: Effect of labelling methods and peptide sequence
114. Technetium-99m labeling of DNA oligonucleotides
115. 99mTc]tricine: A useful precursor complex for the radio-labeling of hydrazinonicotinate protein conjugates
116. 99mTc using aminocarboxylates as coligands
117. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins
118. 99mTc-labeled hydrazino nicotinamide derivatized polypeptides and peptides
119. 99mTc labeling of highly potent small peptides
120. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands
121. 99mTc-labeled polypeptides with low in vivo protein binding
122. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment
123. 111 In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo
124. 1-octreotide in vivo
125. Strategies to reduce renal radioactivity levels of antibody fragments
126. 111In-DTPA-conjugated peptides
127. A comparison of cleavable and noncleavable hydrazinopyridine linkers for the Tc-99m labeling of Fab' monoclonal antibody fragments
128. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery
129. The renal handling of amino acids and oligopeptides
130. Chemical design of radiolabeled anti-body fragments for low renal radioactivity levels
131. ε-maleoyl-L-lysine (HML)-conjugated Fab fragments
132. 3]
133. -] in aqueous solution and its reaction with a bifunctional ligand
134. 99mTc-aquaion labels peptide to an unprecedented high specific activity
135. 99mTc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules
136. + intermediate: A novel technetium radiopharmaceutical platform
137. Preparation of cyclopentadienyltricarbonylrhenium complexes using a double ligand-transfer reaction
138. Protein and peptide labeling with (cyclopentadienyl)tricarbonyl rhenium and technetium
139. Synthesis and biological evaluation ofTc-99 m-cyclopentadienyltricarbonyltechnetium-labeled octreotide
140. Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alpha-substituted estradiol complexes
141. 11C]methylpiperidin-4-yl acetate without arterial blood sampling: Methodology of shape analysis and its diagnostic power for Alzheimer's disease
142. Coordination compounds in nuclear medicine